GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBPP.PFD) » Definitions » EPS (Diluted)

Regen BioPharma (Regen BioPharma) EPS (Diluted) : $0.00 (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Regen BioPharma EPS (Diluted)?

Regen BioPharma's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00.

Regen BioPharma's EPS (Basic) for the three months ended in Mar. 2024 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00.

Regen BioPharma's EPS without NRI for the three months ended in Mar. 2024 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00.

During the past 12 months, Regen BioPharma's average EPS without NRIGrowth Rate was -108.60% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 29.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 62.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 47.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Regen BioPharma's highest 3-Year average EPS without NRI Growth Rate was 79.20% per year. The lowest was -16.60% per year. And the median was 44.90% per year.


Regen BioPharma EPS (Diluted) Historical Data

The historical data trend for Regen BioPharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma EPS (Diluted) Chart

Regen BioPharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regen BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regen BioPharma's EPS (Diluted)

For the Biotechnology subindustry, Regen BioPharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's PE Ratio falls into.



Regen BioPharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Regen BioPharma's Diluted EPS for the fiscal year that ended in Sep. 2023 is calculated as

Diluted EPS (A: Sep. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(1.024-0)/0
=

Regen BioPharma's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.122-0)/0
=

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regen BioPharma  (OTCPK:RGBPP.PFD) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Regen BioPharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Regen BioPharma (Regen BioPharma) Business Description

Traded in Other Exchanges
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.